Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation
August 2017 | Volume 16 | Issue 8 | Original Article | 760 | Copyright © 2017
Hasan Khosravi MD,a Michael P. Siegel PhD,b Abby S. Van Voorhees MD,c and Joseph F. Merola MD MMSca,d
aHarvard Medical School, Boston, MA bNational Psoriasis Foundation, Portland, OR cEastern Virginia Medical School, Norfolk, VA dBrigham and Women’s Hospital, Boston, MA
Inverse or intertriginous psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. After reviewing the literature for new treatments, a task force was convened to update a consensus on inverse psoriasis therapy. Short-term treatment continues to be low-potency topical steroids. In order to avoid steroid-induced adverse effects, long-term therapy includes topical immunomodulators, calcitriol, and calcipotriene. Second and third-line therapies include antimicrobials, emollients, and tar-based products. Inverse psoriasis resistant to topical therapy has been shown to respond to botulinum toxin injections, excimer laser therapy, and certain systemic agents (such as anti-TNF and anti-IL12/IL23 therapy). Based on promising results from case reports and prior clinical experience, these systemic agents should be strongly considered in inverse psoriasis resistant to topical therapy. However, they need further evidence-based evaluation. The use of randomized trials and objective severity indices may allow for more robust therapeutic data.
J Drugs Dermatol. 2017;16(8):760-766.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Patients with psoriasis commonly have involvement of the skin fold areas referred to as intertriginous, exural, or inverse psoriasis.These areas are typically marked by less epidermal keratinization and include the axillae, perianal skin, antecubital fossae, popliteal fossae, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds.1 According to the Nurses Health Study and Health Professionals Follow-up Study, the frequency of inverse psoriasis among physician-diagnosed psoriasis is 24%.2 The skin lesions are characterized by shiny, well-demarcated, erythematous plaques with little scaling.1 Interestingly, inverse psoriasis has been found more commonly in obese individuals and is associated with increased risk for psoriatic arthritis or nail involvement1,3; in addition, intertriginous psoriasis occurs in infants and young children, with 4% suffering from localized psoriatic diaper rash.4 Erythema is also increased in inverse psoriasis due to inflammation and secondary changes from friction, perspiration, and maceration. Stemming from these secondary changes, inverse psoriasis can be diagnostically challenging when also considering candidal intertrigo, tinea infection, irritant, or allergic contact dermatitis. Although overlap exists between inverse and genital psoriasis, inverse psoriasis is a distinct entity with a similar high burden of disease; in fact, 38% of patients with genital psoriasis did not have flexural skin involvement, characteristic of inverse psoriasis.5 With respect to genital psoriasis, reported symptoms include itch (86%), pain (44%), burning (49%), dyspareunia (45%), and worsening lesions after intercourse (34%); these symptoms lead to impairments in sexual function and frequency accompanied by fear of sexual relations.6 In one study, 45.8% of patients did not discuss their genital psoriasis with their physician, indicating low awareness of this condition among physicians.7 In comparison, the impact of inverse psoriasis has been analyzed with the Inverse Psoriasis Burden of Disease tool; this scoring system identified notable symptoms including negative body image, pain, ssuring, skin maceration, and embarrassment.8 The tool also demonstrates the greatest impairments in daily activities such as clothing choice and toileting or personal hygiene.8 Historically, the primary treatment for inverse psoriasis included low-potency topical steroids.9 However, there is concern about side effects including atrophy, ulceration, striae, and telangiectasia especially in areas with little epidermal hyperplasia. Therefore, there is an advantage to topical nonsteroidal, systemic, or phototherapy for extensive disease resistant to topicals. New studies have attempted to demonstrate the efficacy of these treatments. This report will summarize these findings while providing an updated consensus on inverse psoriasis therapy.